✨ Free AI Report
Aytu BioPharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aytu BioPharma, Inc.
Company Research

Aytu BioPharma, Inc.: Business Overview, Financials & Competitive Analysis

Aytu BioPharma, Inc. scores 4/10 on the AskCyborg Cyborg Score (Weak). Small-cap pharma facing revenue headwinds with promising pipeline potential, but execution risk is substantial. Aytu BioPharma reported a 16% year-over-year decline in revenue, totaling $13.9 million for the first quarter. With a market capitalization of $22.9M and an EPS of -$3.42, the company faces significant execution challenges despite analyst.

What is Aytu BioPharma, Inc.'s industry? Aytu BioPharma, Inc. (aytubio.com) operates in Specialty Pharmaceuticals. AskCyborg classifies Aytu BioPharma, Inc. under Specialty Pharmaceuticals in its company registry.

Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics, with its primary products treating attention deficit hyperactivity disorder and other pediatric conditions...

4/ 10Weak

Cyborg Score thesis

Small-cap pharma facing revenue headwinds with promising pipeline potential, but execution risk is...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Aytu BioPharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Aytu BioPharma, Inc.

AskCyborg analysts argue the bull and bear cases for Aytu BioPharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aytu BioPharma, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Aytu BioPharma, Inc. Overview

Pro stress-test →

Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics, with its primary products treating attention deficit hyperactivity disorder and other pediatric conditions. The company's business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies.

Strategic Profile

Pro stress-test →

The company is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease. Key prescription products include Adzenys XR-ODT and Cotempla XR-ODT for ADHD treatment across different age groups.

Competitive Landscape

Pro stress-test →

Competitors include Tris Pharma, Novartis, Johnson & Johnson Innovative Medicine, Takeda Pharmaceutical, and Antares Pharma. Aytu competes in the specialty pediatric pharmaceutical space with limited scale compared to major pharma competitors.

Industry Context

Aytu BioPharma, Inc. operates in Specialty Pharmaceuticals.

Key facts

Founded: 2002 · Headquarters: Denver, Colorado · Employees: 127 · Revenue: $62.6M · Market cap: $22.9M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Aytu BioPharma, Inc..

  • Q1 2026 revenue declined 16% year-over-year, signaling portfolio headwinds
  • Rare disease focus (vascular Ehlers-Danlos Syndrome) provides differentiated pipeline opportunity
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025Presented at Planet MicroCap Showcase with product update
  • 2025Commercial availability of EXXUA announced in U.S. market
  • +1 moreTrack every material event for Aytu BioPharma, Inc. as it happens. Explore monitoring →
Get alerted when Aytu BioPharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ADHD & Pediatric PortfolioLarge-cap diversified pharma→ADHD & Specialty PediatricsGlobal specialty pharma→Injectable Specialty PharmaSpecialty drug delivery competitor→

Compare Aytu BioPharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aytu BioPharma, Inc. operates in Specialty Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Top companies in Specialty Pharmaceuticals by Cyborg Score

Browse Specialty Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Aytu BioPharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aytu BioPharma, Inc. and its top competitor on Cyborg Score”
“What did Aytu BioPharma, Inc. do this quarter?”
“Is Aytu BioPharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Aytu BioPharma, Inc. do?+
Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics, with its primary products treating attention deficit hyperactivity disorder and other pediatric conditions...
What is Aytu BioPharma, Inc.'s Cyborg Score?+
Aytu BioPharma, Inc. has a Cyborg Score of 4/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aytu BioPharma, Inc.'s main competitors?+
Named competitors include ADHD & Pediatric Portfolio, ADHD & Specialty Pediatrics, Injectable Specialty Pharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Aytu BioPharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aytu BioPharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aytu BioPharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Catalyst Pharmaceuticals, Inc.7Achieve Life Sciences, Inc.7Assertio Holdings, Inc.7Viatris Inc.7Xeris Biopharma Holdings, Inc.6Allergy Therapeutics PLC6Eagle Pharmaceuticals Inc.6Santhera Pharmaceuticals Holding AG6Supernus Pharmaceuticals, Inc.5Amphastar Pharmaceuticals, Inc.Top companies in Specialty Pharmaceuticals by Cyborg Score